ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SCNX vs ACXP // 10Y YIELD & FRED MACRO BETA

Scienture Holdings Inc. (NASDAQ) VS. Acurx Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: SCNX 2 — ACXP 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SCNX VS. ACXP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SCNX ACXP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 76.80% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 SCNX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 37.8 33.0 +4.80 SCNX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $5.7M $5.9M -$216.0K ACXP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SCNX REV ACXP REV SCNX GROSS % ACXP GROSS % SCNX FCF ACXP FCF
FY 2025 $431.6K $0 76.8% — -$13.4M -$6.8M
FY 2024 $136.6K $0 4.4% — -$14.3M -$10.4M
FY 2023 $1.4M $0 — — -$2.2M -$9.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SCNX // BETA —
ACXP // BETA —